Journal of the American College of Cardiology · 2024
When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review.
СтатьяОбзорПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bejjani Antoine, Khairani Candrika D, Assi Ali, Piazza Gregory, Sadeghipour Parham, Talasaz Azita H, Fanikos John, Connors Jean M, Siegal Deborah M, Barnes Geoffrey D, Martin Karlyn A, Angiolillo Dominick J, Kleindorfer Dawn, Monreal Manuel, Jimenez David, Middeldorp Saskia, Elkind Mitchell S V, Ruff Christian T, Goldhaber Samuel Z, Krumholz Harlan M, Mehran Roxana, Cushman Mary, Eikelboom John W, Lip Gregory Y H, Weitz Jeffrey I, Lopes Renato D, Bikdeli Behnood
Аннотация
For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism treatment. However, randomized controlled trials suggest that DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease. DOACs do not provide a net benefit in conditions such as embolic stroke of undetermined source. Their efficacy is uncertain for conditions such as left ventricular thrombus, catheter-associated deep vein thrombosis, cerebral venous sinus thrombosis, and for patients with atrial fibrillation or venous thrombosis who have end-stage renal disease. This paper provides an evidence-based review of randomized controlled trials on DOACs, detailing when they have demonstrated efficacy and safety, when DOACs should not be the standard of care, where their safety and efficacy are uncertain, and areas requiring further research.